All In Biotech

Drug Trial Radar · NCT07465913

Rocklatan vs Latanoprost Post-DSLT

Outcomes of Direct Selective Laser Trabeculoplasty With the Post-treatment Addition of Combination Netarsudil and Latanoprost vs Latanoprost Monotherapy

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

May 6, 2027

Study completion May 6, 2027

Sponsor

Lead sponsor
Eye Centers of Southeast TexasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sengi
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.

Conditions

  • Glaucoma

Interventions

  • Rocklatan 0.02%-0.005% Ophthalmic SolutionDrug

    netarsudil and latanoprost 0.02%/0.005%

  • Latanoprost 0.005% Ophthalmic SolutionDrug

    Latanoprost 0.005%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in mean diurnal intraocular pressure (IOP) from baselineTime frame: 3 months post-treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye Centers of Southeast Texas

    Beaumont, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.